M&A Deal Summary |
|
|---|---|
| Date | 2016-07-20 |
| Target | Shire - Pre-clinical Programmes |
| Sector | Life Science |
| Buyer(s) | Chronos Therapeutics |
| Sellers(s) | Shire |
| Deal Type | Divestiture |
SEARCH BY
Chronos Therapeutics Ltd. is a privately held biotechnology company focused on diseases of ageing, brain and nervous system disorders. Chronos has a dedicated laboratory in Oxford, which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen[TM].
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Ireland M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 5,548 |
| Revenue | 6.4B USD (2015) |
Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 3 |
| Country: Ireland M&A | 1 of 2 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-01-11 |
Baxalta
Deerfield, Illinois, United States Baxalta Incorporated is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. |
Buy | $32.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-04 |
Shire - MRT platform
Dublin, Ireland Shire plc - MRT platform is a mRNA therapy platform. |
Sell | - |
